Leukemia
Leukemia
Over the past 20 years, advances in the treatment of chronic myeloid leukemia (CML) have made this type of cancer highly treatable, such that most patients can live long and productive lives. Today, people diagnosed with CML who are treated with targeted medications have similar life expectancies as people without CML.
Leukemia
By Chase Doyle
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs.
Leukemia
By Chase Doyle
The targeted therapy Calquence (acalabrutinib), a Bruton tyrosine kinase (or BTK) inhibitor, which is approved by the FDA for the treatment of patients with non-Hodgkin lymphoma has now demonstrated long-term remissions as first-line treatment of patients with chronic lymphocytic leukemia (CLL), according to data presented at the 2020 ASCO annual meeting.
Leukemia
By Dana Taylor
Results of a recent study show that the use of Imbruvica plus Venclexta in patients with CLL who had not received any previous therapy for CLL had long-term remissions of the disease.
FDA Approvals, News & UpdatesLeukemia
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
Leukemia
A new long-term study suggests that the choice of treatment for patients with chronic lymphocytic leukemia should be based on the risk level of their disease. Patients at high risk should consider joining a clinical trial with novel agents.
Leukemia
Long-term results of a pivotal trial of acalabrutinib verify that it is effective and safe as first-line therapy for patients with chronic lymphocytic leukemia.
Leukemia
According to findings from a large clinical trial, the combination of ibrutinib and ublituximab is effective in treating patients with chronic lymphocytic leukemia.
Leukemia
The ASCEND trial confirmed that acalabrutinib, a next-generation targeted treatment, is more effective than traditional chemoimmunotherapy in patients with relapsed chronic lymphocytic leukemia.
Leukemia
Recently reported data show that fixed-duration treatment with venetoclax and obinutuzumab for 12 months is effective and tolerable in some patients with chronic lymphocytic leukemia.